GLG
Get Started
GLG

Shaping the Future of Healthcare with AI

The healthcare industry represents one of the most promising applications for AI and machine learning. These technologies could transform how we deliver patient care, discover new therapeutics, control healthcare costs, and eliminate time-consuming administrative tasks.  GLG brought together leading subject-matter experts to discuss how AI and machine learning will drive the future of patient care and […]

Digital Health Platforms Buy and Build

The concept of connected care has created integrated platforms that house software-based products, offerings and services related to healthcare. The aim is to keep people healthy through predictive diagnoses, to optimise the delivery of patient care through offerings that show a clear benefit, and to respond to growing demands for cost saving solutions. So what […]

The State of Pharma Contract Development and Manufacturing Organizations

When we talk about contract drug and manufacturing organizations (CDMOs), we are really talking about a diverse group of companies that serve pharma/biotech/academia in a variety of ways, from discovery through to commercialization opportunities. These companies constitute a very broad and quite fragmented ecosystem, which continues to grow because (ultimately) Big Pharma intends to continue […]

What We Can Do about Wasted Pharmaceuticals

The medicine is still perfectly good. Millions of uninsured or underinsured people need the drugs. Yet the pharmaceutical industry incinerates billions of dollars’ worth of unopened, unused, and unexpired drugs each year in America. This waste leads to both economic and environmental challenges. The good news is the problems companies create when they destroy unused […]

Challenges and Opportunities in Australia’s Radiology Industry

Australia’s aging population creates a changing environment for health service businesses in the nation and, in particular, radiology service providers. Specifically, radiology is the diagnostic approach to detect illnesses using radiation. Ultrasound, X-rays, MRIs, PET/CT (positron emission tomography and computer-aided tomography) scans, and nuclear medicine. For an informed view of what likely lies ahead, GLG’s […]

The Inflation Reduction Act: What Drugmakers Should Know

The Inflation Reduction Act is one of the Biden administration’s signature pieces of legislation, and its drug pricing provisions should bring major changes to America’s pharmaceutical industry. New rules will likely affect the bottom lines of drugmakers, trim margins for pharmacy benefit managers, and lower out-of-pocket costs for Medicare beneficiaries. But changing the intricacies of […]

Looking at the Australian National Disability Insurance Scheme (NDIS)

According to a report by the Australian Associated Press, there is bipartisan support for the National Disability Insurance Scheme (NDIS) despite ongoing criticism over rising costs. The cost of NDIS is anticipated to climb $8.8 billion over the next four years and approach $50 billion annually by 2025-26. Nevertheless, Australia’s prime minister says that the […]

Speaker Biographies

Hilary Malone PhD, has over 25 years of experience in global drug development, regulatory &government affairs, manufacturing and commercialization within the biopharma industry. Hilary hassignificant board level and executive committee experience including large scale organizationalrestructuring/transformation/integration, major M&A, biotech start-up, capital raising, investorrelations and pre-IPO.​

Hilary is currently CEO of Stylus Medicine, a private genetic medicine biotech company. Previously sheserved as CEO of a Series-A neuroscience company. Prior to these roles, Hilary served as COO & EVP atValo Health Inc., Chief Regulatory Officer & SVP at Sanofi Inc., and Chief Regulatory Officer & SVP atPfizer and Wyeth. Previous experience also includes senior regulatory and drug development roles atReata Pharmaceuticals Inc., AstraZeneca plc and GlaxoSmithKline plc.​

Hilary also serves on the Board of Directors of Hansa Biopharma and Adthera Bio. Hilary holds a PhD inMolecular Neuropharmacology and a BSc in Physiology.

Dr. Thomas Lönngren is Director at his own company PharmaExec Consulting AB. He is the Chairman of the Board of directors at Egetis Therapeutics AB, Sweden. Dr Lönngren also serves as board member at Compass Pathways PLC, London UK and NDA Group, Sweden. He acts as advisor to the following companies and organizations: NDA group, Sweden, Sweden, Artis Venture, San Francisco, US, Fujimoto Japan, Skin2Neuron Pty Ltd, Sydney, Australia, US, Special advisor to the Centre for Innovation in Regulatory Science (CIRS), London UK. From 2001 until2011, Mr.Lönngren served as the Executive Director of the European Medical Agency. He was previously Deputy General Director of the Swedish Medical Product Agency until 2000. He has a degree in pharmacy and MSc in Social and Regulatory Pharmacy from Uppsala University. He is also an Honorary Member of the Royal Pharmaceutical Society of Great Britain, Honorary Fellow of the Royal College of Physicians in Great Britain, Honorary Doctorate from the University of Uppsala, Honorary Doctorate from University of Bath, UK.

Speaker Biographies

Marie-Anne Aymerich

Marie-Anne has built a portfolio of senior advisory and non-executive roles, following a successful international career in the FMCG and Luxury sectors. She is a non-executive director of Haleon, a FTSE100 company listed in 2022 after the demerger from GSK. She is also chairwoman of Haleon Environment and Societal Sustainability committee. She is the executive director of the Pierre Fabre Group where she also sits on the Strategic Committee, and she is a Board Member of The Academy of St. Martin-in-the-Fields, one of the world’s most prestigious chamber orchestras. She is also an angel investor and focuses her time and investments on start-ups with the strongest purpose and impact.

Marie-Anne is also a regular lecturer at HEC Paris on purposeful leadership, and she has created a serious game called “Planet Purpose” to upskill people on sustainability and purpose. Throughout her 35year executive career she delivered a strong track-record of business performance and growth in brands and portfolio in both developed and emerging economies.

As a senior leader with Unilever, she led a number of different personal care categories across France, Spain and the USA – including managing the Dove brand worldwide and culminating in leading Unilever’s global Oral Care division. She also worked for LVMH as Brand General Manager of Dior Perfumes and Cosmetics worldwide. Marie-Anne was also Vice-President of Imagine for Margo – Children with Cancer for ten years, a charity she helped found in 2011 with the goal of eradicating children’s cancer. The charity is the #1 charity focused on child cancer in France and has fundraised more than €14m since its creation. Marie-Anne is a graduate from HEC Paris. She is married and has two children aged 29 and 26.

Patrick Jephson

Patrick Jephson is a consultant, journalist, broadcaster and New York Times bestselling author, based in Washington D.C. He is a published authority on corporate and personal branding and crisis communications, addressing conferences worldwide as well as events at the U.S. State Department, the American University and the Annenberg School for Communication and Journalism.

With more than twenty-five years’ experience in the government, luxury and family office sectors, Patrick’s portfolio has included globally admired brands as well as national agencies and NGOs. He has also worked on reputation and legacy briefs with European, Middle Eastern and Asian families, including royalty. He now writes, presents, and advises on factual and drama TV programs, appearing on every major American and many international networks. He was recently an expert consultant to the award-winning Netflix series The Crown and provided live commentary on the Coronation of King Charles.

Patrick owes much of his practical communications and protocol experience to Princess Diana, who chose him to be her equerry and only private secretary/chief of staff. He served the Princess for eight years, responsible for all aspects of her public life, global humanitarian initiatives, and private organization. Having worked for an internationally high-profile woman (and as the father of two professionally successful daughters) he feels a special affinity for cross-cultural, gender and perception issues.

Patrick was born and raised in Ireland and holds a master’s degree in political science from Cambridge University. As an officer in the British Royal Navy, he served all over the world before being selected for royal duty. He is a citizen of the U.K., U.S.A., Ireland, and Canada.